AZN (LSE) - AstraZeneca PLC

Exchange: London Exchange • Country: United Kingdom • Currency: GBX • Type: Common Stock • ISIN: GB0009895292
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Web URL: https://www.astrazeneca.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for AZN (LSE) - AstraZeneca PLC

Classification

Market Cap in USD 2,065m
Sector Healthcare
Industry Drug Manufacturers-General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1993-05-12

Ratings

Fundamental 4.61
Dividend 5.69
Performance 5y 7.78
Rel. Performance vs Sector -0.09
Analysts -
Fair Price Total Ret. 115.75
Fair Price DCF todo

Technical

Growth TTM 15.05%
CAGR 5y 16.50%
CAGR / Mean Drawdown 5y 2.31
Sharpe Ratio TTM 0.45
Alpha vs SP500 TTM 9.93
Beta vs SP500 5y weekly 0.27
CAPM 5.96%
Average Daily Range 2m 1.81%
Reversal Oscillator 82.78
Volatility GJR Garch 1y 22.44%
Price / SMA 50 3.82%
Price / SMA 200 0.9%
Current Volume 1538.2k
Average Volume 20d 1999.7k

Dividends

Yield TTM 2.10%
Yield on Cost 5y 4.50%
Dividends CAGR 5y 1.88%
Consistency of Dividends all time 98.1%